Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label, non-randomized, multi-center, sequential group, safety, tolerance, and
Pharmacokinetic study of a single dose of CMX001 administered at 2 mg/kg of ideal body weight
rounded to the closest 20 mg in fasted healthy control subjects compared with that in fasted
subjects with moderate and severe hepatic impairment.